Enzelsberger H, Kurz C, Helmer H, Mittermayer F
I. Univ.-Frauenklinik Wien.
Geburtshilfe Frauenheilkd. 1995 May;55(5):240-3. doi: 10.1055/s-2007-1023310.
Detrusor instability is the second most common cause of femal urinary incontinence. Oxybutynin chloride anticholinergic action with direct muscle-relaxant properties. 39 women with persistent-urgeincontinence participated in a pilot study of intravesical oxybutynin application. Patients received either 20 mg oxybutynin or placebo as 40 ml sterile sodium chloride solution administered intravesically over a period of 10 days. Urodynamic assessment as well as micturition protocols were performed before and after treatment. The intravesical oxybutynin-application was significantly better than the placebo application concerning reduction of pollakisuria and nycturia. Oxybutynin also increased bladder capacity more than in the placebo-treated group (p < 0.01) and provided an improvement of bladder compliance (p < 0.05). No local or systemic side effects were observed which would have immediately terminated the oxybutynin treatment.
逼尿肌不稳定是女性尿失禁的第二大常见原因。氯化奥昔布宁具有抗胆碱能作用及直接的肌肉松弛特性。39名持续性尿急失禁的女性参与了一项膀胱内应用奥昔布宁的试点研究。患者接受20毫克奥昔布宁或安慰剂，以40毫升无菌氯化钠溶液膀胱内给药，为期10天。在治疗前后进行尿动力学评估以及排尿记录。在减少尿频和夜尿方面，膀胱内应用奥昔布宁明显优于应用安慰剂。奥昔布宁还比安慰剂治疗组更能增加膀胱容量（p < 0.01），并改善膀胱顺应性（p < 0.05）。未观察到会立即终止奥昔布宁治疗的局部或全身副作用。
